Literature DB >> 7986181

A brief history of the use of interferons as treatment of multiple sclerosis.

L Jacobs1, K P Johnson.   

Abstract

Interferons (IFNs) are a family of glycoproteins that are naturally secreted by certain cells in response to viral infection. The naturally occurring IFNs confer protection on other cells, preventing them from becoming infected, a phenomenon referred to as "virus interference" by Isaacs and Lindenmann in the first description of these proteins. In addition to their antiviral properties, the IFNs also have complex immunomodulatory, antiproliferative, and hormonelike activities, which are not completely understood.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7986181     DOI： 10.1001/archneur.1994.00540240089022

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


  12 in total

Review 1.  Therapeutic strategies in multiple sclerosis. I. Immunotherapy.

Authors:  R Hohlfeld
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-10-29       Impact factor: 6.237

2.  Multiple sclerosis: An old drug plays a new trick.

Authors:  Hartmut Wekerle; Edgar Meinl
Journal:  Nature       Date:  2013-10-09       Impact factor: 49.962

Review 3.  Magnetic resonance imaging of multiple sclerosis lesions. Measuring outcome in treatment trials.

Authors:  J H Simon
Journal:  West J Med       Date:  1996-06

Review 4.  HERVs in neuropathogenesis.

Authors:  Tove Christensen
Journal:  J Neuroimmune Pharmacol       Date:  2010-04-27       Impact factor: 4.147

Review 5.  Detrimental effects of chronic hypothalamic-pituitary-adrenal axis activation. From obesity to memory deficits.

Authors:  J Raber
Journal:  Mol Neurobiol       Date:  1998-08       Impact factor: 5.590

Review 6.  Interferon-beta treatment for multiple sclerosis.

Authors:  Robert A Bermel; Richard A Rudick
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

7.  Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.

Authors:  C Pozzilli; S Bastianello; T Koudriavtseva; C Gasperini; A Bozzao; E Millefiorini; S Galgani; C Buttinelli; G Perciaccante; G Piazza; L Bozzao; C Fieschi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-09       Impact factor: 10.154

8.  Interferon-β suppresses murine Th1 cell function in the absence of antigen-presenting cells.

Authors:  Nicolas Boivin; Joanie Baillargeon; Prenitha Mercy Ignatius Arokia Doss; Andrée-Pascale Roy; Manu Rangachari
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

Review 9.  Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex).

Authors:  Stanley L Cohan; Barry A Hendin; Anthony T Reder; Kyle Smoot; Robin Avila; Jason P Mendoza; Bianca Weinstock-Guttman
Journal:  CNS Drugs       Date:  2021-07-06       Impact factor: 5.749

Review 10.  Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis.

Authors:  F Piehl
Journal:  J Intern Med       Date:  2020-12-20       Impact factor: 8.989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.